Melinta Therapeutics Overview
- Year Founded
-
2000
- Status
-
Private
- Employees
-
290
- Latest Deal Type
-
Debt
- Financing Rounds
-
17
- Investments
-
3
Melinta Therapeutics General Information
Description
Developer of novel small-molecule antibiotics intended to focus on the treatment of resistant infections. The company develops treatments for bacterial infectious diseases, particularly respiratory tract infections and staphylococcal infections and is focused on treating community-acquired bacterial pneumonia, as well as gonorrhea and other indications, enabling clients to get safe and differentiated antibiotics for acute care.
Contact Information
Website
www.melinta.comCorporate Office
- 389 Interpace Parkway
- Suite 450
- Parsippany, NJ 07054
- United States
Corporate Office
- 389 Interpace Parkway
- Suite 450
- Parsippany, NJ 07054
- United States
Melinta Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Melinta Therapeutics Comparisons
Industry
Financing
Details
00000
000000
Melinta Therapeutics Competitors (25)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Spero Therapeutics | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 000000000 | 00000 |
| BioVersys | Venture Capital-Backed | Basel, Switzerland | 00 | 00000 | 00000000000 | 00000 |
| Achaogen | Formerly VC-backed | South San Francisco, CA | 00 | 00000 | 0000000000. | |
| Destiny Pharma | Formerly PE-Backed | Brighton, United Kingdom | 00 | 000.00 | 00000000 | 000.00 |
| NovaBiotics | Venture Capital-Backed | Aberdeen, United Kingdom | 00 | 000.00 | 00000 00000 | 000.00 |
Melinta Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Melinta Therapeutics Patents
Melinta Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2018360502-A1 | Synthesis of boronate ester derivatives and uses thereof | Active | 01-Nov-2017 | 0000000000 | |
| AU-2018360502-B2 | Synthesis of boronate ester derivatives and uses thereof | Active | 01-Nov-2017 | 0000000000 | |
| EP-3285776-B1 | Dosage regimen of vaborbactam and meropenem for treating bacterial infections in subjects with reduced renal function | Active | 24-Apr-2015 | 000000000 | 0 |
| EP-3285776-A1 | Methods of treating bacterial infections | Active | 24-Apr-2015 | 000000000 | |
| EP-3285776-A4 | Methods of treating bacterial infections | Active | 24-Apr-2015 | A61K31/69 |
Melinta Therapeutics Executive Team (28)
| Name | Title | Board Seat |
|---|---|---|
| Jennifer Sanfilippo | General Counsel and Chief Compliance Officer | |
| Christine Miller | President, Chief Executive Officer & Board Member | |
| Susan Blum | Chief Financial Officer | |
| Sunitha Lakshminarayanan | Chief Technology Officer | |
| Kristen Allgor | Chief Human Resources Officer |
Melinta Therapeutics Board Members (28)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000 0000000000 | Deerfield Management | Board Member | 000 0000 |
| 000000000 000000 | Melinta Therapeutics | President, Chief Executive Officer & Board Member | 000 0000 |
| 00000000 000000000 | Melinta Therapeutics | General Counsel and Chief Compliance Officer | 000 0000 |
| 00000000 0000 | Deerfield Management | Board Member | 000 0000 |
| 000000 00000000 | Deerfield Management | Board Member | 000 0000 |
Melinta Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Melinta Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Melinta Therapeutics Acquisitions (3)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| AstraZeneca (US Rights for Toprol-XL) | 06-Apr-2022 | 0000000000 | Buildings and Property | ||
| The Medicines Company Infectious Disease Care Group | 05-Jan-2018 | 0000000000 | 00000 | Drug Discovery | 000000 00 |
| Cempra Pharmaceuticals | 03-Nov-2017 | Merger/Acquisition | Pharmaceuticals | 0000 0000 |
Melinta Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Melinta Therapeutics FAQs
-
When was Melinta Therapeutics founded?
Melinta Therapeutics was founded in 2000.
-
Who is the founder of Melinta Therapeutics?
Peter Moore Ph.D, Thomas Steitz Ph.D, and William Jorgensen Ph.D are the founders of Melinta Therapeutics.
-
Who is the CEO of Melinta Therapeutics?
Jennifer Sanfilippo is the CEO of Melinta Therapeutics.
-
Where is Melinta Therapeutics headquartered?
Melinta Therapeutics is headquartered in Parsippany, NJ.
-
What is the size of Melinta Therapeutics?
Melinta Therapeutics has 290 total employees.
-
What industry is Melinta Therapeutics in?
Melinta Therapeutics’s primary industry is Biotechnology.
-
Is Melinta Therapeutics a private or public company?
Melinta Therapeutics is a Private company.
-
What is Melinta Therapeutics’s current revenue?
The current revenue for Melinta Therapeutics is 000000.
-
How much funding has Melinta Therapeutics raised over time?
Melinta Therapeutics has raised $120M.
-
Who are Melinta Therapeutics’s investors?
Deerfield Management has invested in Melinta Therapeutics.
-
Who are Melinta Therapeutics’s competitors?
Spero Therapeutics, BioVersys, Achaogen, Destiny Pharma, and NovaBiotics are some of the 25 competitors of Melinta Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
